The Centers for Medicare and Medicaid (CMS) recently held a comment period as they reconsidered limitations on scans to detect Dementia. The current system only allows for a single PET scan to be covered by CMS for an Alzheimer’s patient enrolled in a clinical trial. The result of this is that it becomes difficult to determine whether the treatment the participating patient is undergoing has improved their status. Removing this limitation makes strong improvements towards treatment of a disease that is still not fully understood and we wholeheartedly support this and similar measures.

Read the letter